Biocon Q2 FY27 Results: Operational Resilience Despite Profitability Pressures
Biocon Ltd · Investor Presentation · 04 Nov 2026, 8:40 pm
Biocon Q2 FY27 Results: Operational Resilience Despite Profitability Pressures Biocon reported Q2 FY27 revenue from operations of ₹4,389 Cr, up 2% YoY, while EBITDA fell 7% YoY to ₹865 Cr (20% margin). Net profit before exceptional items declined 52% YoY to ₹44 Cr. Biosimilars revenue rose 3% YoY to ₹2,809 Cr, and Generics grew 10% YoY to ₹774 Cr with margins up over 700 bps. Services revenue dropped 9% YoY to ₹833 Cr but rebounded 13% QoQ. Management anticipates a stronger H2 FY27 driven by biosimilar launches, expanded insulin capacity, and progressive Services recovery.
Original exchange filing (PDF)
More announcements from Biocon Ltd
- Press Release · 18 Nov 2026
- Press Release · 16 Nov 2026
- Intimation on Schedule of Meetings with Analyst(s)/institutional Investor(s) · 12 Nov 2026
- Earnings Call Transcript for Q2 FY27 · 12 Nov 2026
- Audio and Video Recording of Q2 FY27 Earnings Call · 05 Nov 2026
- Communication regarding withholding of final dividend for the FY 2025-26 · 04 Nov 2026
- Change in Senior Management Personnel · 04 Nov 2026
- Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on November 04, 2026. · 04 Nov 2026
